SCHEMBL6085669

SCHEMBL6085669

O=C(Nc1ccc(-c2n[nH]cc2-c2nc3ccccc3o2)cc1)C(C1CCCCC1)C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
HPGD P15428 5/20 0.47
KDM4E B2RXH2 5/20 0.47
TP53 P04637 5/20 0.47
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 4/20 0.47
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
USP2 O75604 2/20 0.43
TSHR P16473 2/20 0.43
GAA P10253 1/20 0.43
STAT3 P40763 1/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
RXFP1 Q9HBX9 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085441 0.87 RXFP1 (0.42) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6085642 0.85 MAPT (0.55) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6084882 0.84 KDM4E (0.59) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6085323 0.83 MAPT (0.55) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6085947 0.82 NPC1 (0.49) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6085907 0.81 MAPT (0.49) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6085011 0.81 TP53 (0.52) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6086017 0.81 ALDH1A1 (0.58) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6086529 0.80 NPC1 (0.54) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6086476 0.80 RAB9A (0.70) MAPTSMN1; SMN2NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885SMN1; SMN2 831/4885NPC1 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.